Acute Coronory Disease Background information for medical media outside the US only This selection gives an overview on background material for Acute Coronory Disease available on the Boehringer Ingelheim corporate website.

Press Releases

• 27 March 2008Novel oral anticoagulant Pradaxa® (dabigatran etexilate) approved by the European Commission
• 25 January 2008European Medicines Agency recommends approval of novel oral anticoagulant, dabigatran etexilate (Pradaxa®)
• 17 January 2008Boehringer Ingelheim announces enrolment completion of the largest atrial fibrillation outcomes trial - The RE-LY™ Study
• press release archive

Documents

• Fact sheet: Dabigatran Etexilate - A Breakthrough in Anticoagulation - PDF (55 KB)
• Fact sheet: Dabigatran Etexilate - PDF (63 KB)
• RE-VOLUTION: Thromboembolic Disease - Clinical Trials - PDF (1.1 MB)
• Backgrounder: Boehringer Ingelheim at a glance - PDF (2,2 MB)
• Backgrounder: Dabigatran Etexilate - A brief history - PDF (35 KB)
• Backgrounder: Venous Thromboembolism (VTE) - PDF (51 KB)
• Annual Report 2007: Page 56 - PDF (4.9 MB)